Experiences with treprostinil in the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a chronic condition of elevated pulmonary arterial pressures with associated increases in pulmonary vascular resistance leading to right ventricular failure, which was almost uniformly fatal prior to the introduction of pulmonary hypertension specific therapy...
Main Authors: | Amanda R. Stream, Todd M. Bull |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-10-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/1753465812455368 |
Similar Items
-
Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
by: Pugliese SC, et al.
Published: (2016-01-01) -
Treprostinil for pulmonary hypertension
by: Nika Skoro-Sajer, et al.
Published: (2008-06-01) -
INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
by: Nicholas S. Hill, et al.
Published: (2022-07-01) -
Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
by: Carlo Arevalo, et al.
Published: (2022-01-01) -
An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
by: Marcin Kurzyna, et al.
Published: (2017-12-01)